The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting growing shareholder scrutiny over international expansion strategies, activist investor Ancora is urging H.B. Fuller to abandon its acquisition bid for the UK-based company AMS. According to reports, the activist believes that pursuing this deal is not in the best interest of shareholders, calling instead for a focus on capital structure optimization. This public opposition places significant pressure on management to re-evaluate the feasibility of expanding into the British market at this time.
Market data indicates that the proposed bid for AMS exceeds £600 million ($806 million), raising concerns from Ancora that the deal could push the company's leverage ratio above 4.0x net debt to EBITDA (per MarketScreener data). Compared to peers in the specialty chemicals sector, H.B. Fuller currently trades at a P/E ratio of approximately 20.4x, similar to competitors like Avient Corp (per Investing.com data). Ancora, which holds a stake of over 2% in the company, expressed concerns that the acquisition would undermine management's credibility following previous commitments to prioritize deleveraging.
Sign in to access this content
Sign InAt the close on May 22, 2026, H.B. Fuller's stock price stood at $57.78, marking a 2.5% gain for that session. Traders are now closely watching for the board's response to Ancora's demands for a full strategic review, which could include a potential sale of the company. Looking ahead at the economic calendar, investors are awaiting the FOMC minutes on May 20, 2026, for insights into future financing costs, alongside UK inflation data which may impact the economic valuation of British target firms.